Complement Activation, Immunogenicity, and Immune Suppression as Potential Side Eff ects of Liposomes - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 334

inhibition by soluble complement receptor type 1. Transfusion 37, pp.
150-159.
91. van de Wert, M., and Moller, E. H. (2008). Immunogenicity of
biopharmaceuticals: causes, methods to reduce immunogenicity, and
biosimilars, In Immunogenicity of Biopharmaceuticals ” (M. van de Wert
and E. H. Moller, eds.), pp. 97-111. Springer, AAPS Press.
92. Venkatraman, S. S., Ma, L. L., Natarajan, J. V., and Chattopadhyay, S.
(2010). Polymer- and liposome-based nanoparticles in targeted drug
delivery. Front. Biosci. (Schol. Ed.) 2, pp. 801-814.
93. Wagner, V., Dullaart, A., Bock, A.-K., and Zweck, A. (2006). The emerging
nanomedicine landscape. Nature Biotechnol . 24, pp. 1211-1217.